Pharma vs The IRA — Industry Leaders React To Merck Lawsuit

 
• By Scrip Team

Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.

business people on the move
Which way will industry move after the Merck lawsuit? • Source: Shutterstock

After news that Merck & Co., Inc. filed a lawsuit against the US government over Medicare drug pricing negotiation policies in the Inflation Reduction Act (IRA) broke on 6 June, one question now is if more companies will follow Merck’s lead. 

While the drug negotiation policies are expected to have a more direct impact on big pharma companies initially, biotech companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip